Search the Newsreel

Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed?

Candel Therapeutics (CADL) saw its net loss widen significantly in Q2 2026 to US$38.91 million, with first-half losses reaching US$47.77 million, marking a sharp shift from prior-year profitability. Despite a 26.4% share price increase, this financial performance raises concerns about funding and potential dilution, …

Is Strong EMPEROR Trial Enrollment and Retention Altering The Investment Case For Stoke Therapeutics (STOK)?

Stoke Therapeutics' Phase III EMPEROR trial for zorevunersen in Dravet syndrome has exceeded its 150-patient enrollment goal, reaching 162 patients with no discontinuations, which is expected to strengthen confidence as the company approaches regulatory milestones. This positive development could influence the investment narrative, with …

Alaunos (TCRT) EPS and Revenue: EPS Does Not Reach the Reported Estimate; Price Reaction: The Session Ends Near the Prior Level - Analyst Coverage Count

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

Amylyx Pharmaceuticals has announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at $35.50 per share, aiming to raise $500.2 million before deductions. The company plans to use the net proceeds for pre-commercial activities for avexitide, research …

Artiva Biotherapeutics CMO sells $5,148 in stock

Artiva Biotherapeutics' Chief Medical Officer, Subhashis Banerjee, sold 429 shares of company stock for $5,148 after exercising employee stock options. These transactions, conducted under a Rule 10b5-1 trading plan, highlight recent insider activity. The company also recently received FDA RMAT designation for its AlloNK …

Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics

Robbins LLP, a shareholder rights law firm, is investigating Sionna Therapeutics (NASDAQ: SION) following a 92% stock drop. The investigation comes after the company reported disappointing results from its Phase 2a study of SION-719 for cystic fibrosis, failing to meet its key activity endpoint. …

Why Eton Pharmaceuticals Is Top of the Class Today

Hong Kong Stocks in Focus | Simcere Pharmaceutical (02096) rises over 5% in early trading as it releases interim results today, driven by strong growth in innovative drugs and business development revenue

LG Energy Solution Starts Production at 35-GWh Michigan Battery Plant

LG Energy Solution has started production at its new battery manufacturing facility in Lansing, Michigan, as the South Korean company expands its North American supply base for both energy storage systems and electric vehicles. The 226-acre plant is designed to reach more than 35 …

Universal Technical Institute (UTI) Stock Dropped, So What Is Driving Attention Now?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Universal Technical Institute (UTI) drew fresh investor attention after entering a new US$200 million senior secured revolving credit agreement that refinances its prior facility and …

Telix Pharmaceuticals (ASX:TLX) Shares Rise Today as H1 Revenue Climbs 22% to US$477 Million

Telix Pharmaceuticals (ASX:TLX) saw its shares rise as it reported a 22% increase in H1 2026 revenue to US$477 million, with a gross margin of 55%. Adjusted EBITDA surged by 146% to US$52 million, and the company achieved a profit after tax of US$38 …

H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Hold Rating

H.C. Wainwright has reiterated its Hold rating for Heron Therapeutics (HRTX.US). The article does not provide further details on the reasons for this rating or any financial analysis.

Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress

Telix Pharmaceuticals (ASX: TLX) reported robust half-year results, with revenue up 22% to US$477 million and adjusted EBITDA surging 146% to US$52 million. The company made significant progress in pipeline development, strategic collaborations, and global manufacturing expansion. Telix reaffirmed its FY26 revenue guidance of …

Jacobs Solutions Inc (J) Stock Up 3.2% but GF Value Says Overval

Jacobs Solutions Inc (J) saw its stock rise by 3.2% to $147.37 on August 19, 2026, yet GuruFocus's GF Value™ indicates the stock is overvalued by 8.2% compared to its intrinsic value estimate of $136.23. The company has a GF Score™ of 72/100, suggesting …

What's Going On With Eupraxia Pharmaceuticals Inc Stock Wednesday?

Dogwood (DWTX) Earnings Reading: Profit Per Share Clears Its Benchmark in the Current Update; Latest Reaction

Cartesian (RNAC) Earnings Report: EPS Comes in Above Forecast in the Latest Reading; Market Reaction

Regeneron (REGN) Results Review: Profit Per Share Clears Its Benchmark in the Current Update; Closing Reaction

Gain (GANX) Financial Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; After Results: The Stock Gains 1.97% on the Day - Revenue Estimate Trend

Iveda (IVDA) Range: Finishes 4.06% Up at $0.37; Price Context: the Price Remains Bounded by the Supplied Support and Resistance under the Current Snapshot - Earnings Breakout Stocks

Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 31,000 Shares

Neumora Therapeutics insider Daljit Singh Aurora sold 31,000 shares of Neumora Therapeutics stock for $1.65 per share, totaling $51,150. This transaction reduced his position by 38.87% to 48,750 shares. The sale is part of a series of transactions from August 17-19, totaling over 246,000 …

Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 91,690 Shares

Daljit Singh Aurora, an insider at Neumora Therapeutics (NASDAQ:NMRA), sold 91,690 shares of the company's stock for $137,535, significantly reducing his position. This sale is part of several transactions Aurora made during the week. Despite these insider sales and the stock trading near its …

Neumora Therapeutics COO Daljit Aurora sells $431,674 in stock By Investing.com

Daljit Singh Aurora, COO and Development Officer at Neumora Therapeutics, sold 277,773 shares of common stock for approximately $431,674 between August 17 and August 19, 2026, while also acquiring 243,753 shares through stock option exercises. The stock has seen a 52% decline over the …

Akari (AKTX) Financial Results: Profit Per Share Falls Below Its Benchmark in the Latest Session; Price Reaction: Shares Show Limited Movement in the Available Record - Revenue Surprise History

Entrada (TRDA) Earnings Update: Profit Per Share Surpasses Its Benchmark on the Day; Share Move: Shares Move Higher 7.02% - Analyst Earnings Estimate

Viavi (VIAV) Quarterly Figures: EPS Beats Its Estimate on the Day; Closing Reaction: Shares Close 6.36% Lower in the Latest Reading - Diluted EPS Report

Offerpad (OPAD) Results Check: The Available Earnings Metric Delivers a Miss on the Day; Market Reaction: The Share Price Sheds 0.24% in Latest Trading - Annual Report

Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock

Halozyme Therapeutics CEO Helen Torley sold 20,000 shares of the company's stock for over $2 million, executed under a pre-arranged Rule 10b5-1 trading plan. This transaction reduced her holdings by 2.54%. The company recently exceeded analyst estimates with strong quarterly earnings and revenue growth, …

Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8

Roth MKM has reiterated its Buy rating for Gain Therapeutics (GANX.US) and maintained its target price of $8. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Neumora Therapeutics (NMRA) insider plans new stock sale after $329K in recent trades

Neumora Therapeutics (NMRA) officer Daljit Singh Aurora has filed a Rule 144 notice for a planned sale of 61,918 shares of common stock on August 19, 2026, through a broker-assisted cashless sale after exercising employee stock options. This follows previous sales by Aurora in …

Handelsbanken Fonder AB Buys New Stake in Figure Technology Solutions, Inc. $FIGR

Handelsbanken Fonder AB has acquired a new stake of 44,600 shares in Figure Technology Solutions, Inc. (NASDAQ:FIGR), valued at approximately $1.37 million during the second quarter. This move comes as other hedge funds also adjusted their positions, and Figure Technology Solutions reported strong quarterly …

MACOM (NASDAQ: MTSI) CFO sells 7,389 shares at $320–$331

MACOM Technology Solutions Holdings, Inc. (MTSI) CFO John Kober sold 7,389 shares of common stock on August 17, 2026, in multiple open-market transactions. The sales occurred at weighted average prices ranging from approximately $320.48 to $330.82 per share and were executed under a pre-arranged …

Ocular (OCUL) Latest Quarter: The EPS Result Is Above Expectation in the Latest Session; Shares Move 6.54% Up on the Day - Adjusted Earnings Analysis

PMV (PMVP) Latest Quarter: The Available Earnings Metric Delivers a Beat in the Latest Reading; Closing Move: The Stock Records a 3.23% Increase on the Day - Analyst Coverage Count

Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Aurora Daljit Singh

This article is a statement of changes in beneficial ownership of securities for Officer Aurora Daljit Singh at Neumora Therapeutics. It is identified as a Form 4 filing, which indicates a required disclosure of insider trading activity.

Mizuho Financial Group Trims UY Scuti Acquisition Corp (UYSC) Stake Amid Overbought Signals

Mizuho Financial Group Inc reduced its stake in UY Scuti Acquisition Corp (NYSE:UYSC) by selling 132,336 shares at $10.70 each, decreasing its total ownership to 6.10%. This adjustment comes as UYSC, a pre-merger SPAC, shows strong short-term momentum and overbought technical indicators despite a …